Skip to main content
NewslettersWatchlist

Clene Inc(CLNN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Clene (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights

Investor Brand Network - Thu Mar 14, 9:23AM CDT

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced its full year 2023 financial results. In addition, the company provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “In 2024 we will continue to advance our regulatory discussions with the U.S. Food and Drug Administration (‘FDA’) that we anticipate will include new data on biomarkers, as well as additional clinical function and survival data in people living with ALS,” said Rob Etherington, president and CEO of Clene. “Having held our initial discussion with the FDA in the fourth quarter of last year, we have a clear understanding of the additional data required to support an accelerated approval pathway filing for CNM-Au8(R). We believe that we can provide additional supportive evidence to advance discussions with the FDA with the potential to file an NDA later this year.”

To view the full press release, visit https://ibn.fm/AbPh6

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Paid Post: Content produced by Investor Brand Network. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

market news
The close: Major North American indexes higher, led by Nasdaq, amid plethora of mixed earnings
Traders work on the floor at the New York Stock Exchange in New York, Wednesday, May 1.
international business
Trump awarded 36 million more Trump Media shares worth $1.8-billion after hitting price benchmarks
Former President Donald Trump speaks to reporters as he leaves the courtroom for the day at Manhattan criminal court, in New York, U.S., April 30, 2024. Seth Wenig/Pool via REUTERS
investor newsletter
The key to successful investing. Plus, why Fairfax Financial is poised for an extraordinary run
investor happy money
market news
The close: Stocks mixed as Fed leaves investors guessing as to when rate cuts will arrive
NEW YORK, NEW YORK - APRIL 29: Traders work on the floor of the New York Stock Exchange during morning trading on April 29, 2024 in New York City. Stocks opened high Monday morning amid a Federal Reserve rate decision and the monthly jobs report later this week. (Photo by Michael M. Santiago/Getty Images)
inside the market
Tuesday’s analyst upgrades and downgrades
Samuel Drouin-Tardif, an electro-mechanic for Boralex, walks in the snow while looking at a wind turbine in Thetford Mines November 24, 2023.
market news
The close: Major indexes fall after wage data; cannabis shares surge on U.S. regulatory move
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.
market news
The close: Stocks higher as investors focus on Fed moves
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26.
advisor etfs
Why this money manager is venturing back into emerging markets and adding more U.S. tech
Illustration of Andrew Pyle for The Mover. Nov. 5, 2022. Illustration by Joel Kimmel

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).